Home
Scholarly Works
Weight-adjusted Intravenous Reslizumab Attenuates...
Conference

Weight-adjusted Intravenous Reslizumab Attenuates Airway Eosinophilia in Severe Asthmatics compared to 100 mg Subcutaneous Mepolizumab

Authors

Mukherjee M; Aleman F; Kjarsgaard M; Radford K; LaVigne N; Salter B; Sehmi R; Nair P

Publisher

European Respiratory Society (ERS)

Publication Date

September 1, 2017

DOI

10.1183/1393003.congress-2017.pa4768

Name of conference

Monitoring Airway Disease
View published work (Non-McMaster Users)

Contact the Experts team